Dental, Vision & Elective Care

The question

Is the dental-and-vision-and-elective-care cohort priced for a sustained consumer-deferral environment, or for the normal post-rates-cycle recovery pattern that has followed every prior tightening cycle of comparable depth?

Base rates

Healthcare has trailed SPY by a meaningful margin over the trailing twelve months, and elective-consumer-care has been among the worst-performing subsegments across the entire equity market over the trailing twenty-four months. Align Technology, Dentsply Sirona, Henry Schein, and National Vision all trade well below fifteen-year median multiples on trailing EBITDA. That dislocation is the setup.

The reference class is prior consumer-deferral cycles in discretionary healthcare: the 1991 recovery, the 2002-2003 post-dot-com recovery, and the 2010-2011 post-GFC recovery. In each case, elective-care volumes troughed four to six quarters after the peak rate hike, recovered to trend over the following six to eight quarters, and overshot trend by roughly five to ten percent in quarters nine through twelve as deferred demand normalized. The conditional probability of a normal recovery pattern, conditional on the rate cycle turning, is roughly seventy percent across the three reference episodes.

For the basket, trailing same-store comp growth at the retail-optical and dental-services tier has already inflected positive in the most recent two quarters, though the consensus model still extrapolates the prior deferral environment. That is the observable leading indicator that the thesis is already partly in motion.

Defensive characteristics in the cohort are meaningful: Cooper's contact-lens franchise, Henry Schein's consumables distribution, and Sotera's sterilization-services model all carry recurring-revenue profiles with low cyclicality at the gross-profit line. The book is positioned to participate in a cyclical recovery while carrying defensive ballast that absorbs a delayed recovery.

Why consensus is wrong

The sell-side is modeling elective-care volume recovery on a two-to-three-year-delayed timeline relative to the historical reference class. Three pieces of that view do not hold up.

First, the consumer-credit overhang that drove the 2023-2024 deferral was concentrated in the sub-prime and near-prime segments. The elective-dental and elective-vision customer base skews higher-income; the actual volume response to the rate cycle has been smaller in magnitude than models assume, and the recovery has begun earlier. Retail-optical same-store data in the third and fourth quarters of 2025 has already inflected.

Second, the Invisalign adoption curve has a durable structural trajectory that is independent of the cyclical recovery. Clear-aligner penetration of the orthodontic case-start mix remains well below mature-country norms, and the recovery in teen case-starts has been stronger than the recovery in adult case-starts by roughly three hundred basis points. The consensus model blends these into a single ramp; they are actually two different curves.

Third, the dental and sterilization distribution franchises have pricing power that was not destroyed by the cycle. Henry Schein's gross margins stayed inside a hundred-basis-point band through the deferral period; Sotera maintained mid-fifties gross margins despite ethylene-oxide regulatory overhang. Defensible gross-margin structure through the bear part of the cycle is the single strongest predictor of re-rating in consumer-healthcare recoveries.

Position construction

The book has one twenty-percent anchor and three sub-books.

Anchor. Cooper Companies at twenty percent is the purest contact-lens consumables franchise at scale, with daily-silicone-hydrogel penetration driving mix up-shift independent of the cyclical recovery.

Dental, roughly twenty-eight percent. Align Technology at ~16.0% is the Invisalign clear-aligner franchise at a multiple compressed to the low end of its fifteen-year band. Henry Schein at ~12.9% is the dental and medical distribution anchor with pricing power intact through the cycle. Envista at ~5.6% adds imaging and specialty dental. Dentsply Sirona at ~4.2% is the turnaround position in dental consumables and equipment at a valuation that prices a continued structural decline we do not model.

Vision, sterilization, and services, roughly twelve percent. Sotera Health at ~7.7% is the sterilization-services franchise with the regulatory overhang now bounded. National Vision at ~3.5% is the retail-optical recovery position at a multiple reset to the 2009 trough. Evolent Health at ~1.5% is the specialty-care value-based services franchise.

Specialty and asymmetric, roughly twenty-eight percent. Revolution Medicines at ~17.1% is the largest non-anchor holding -- a KRAS-inhibitor oncology platform at a valuation that reflects a single-readout binary rather than the platform breadth we see. BBB Foods at ~5.2% is the consumer-defensive position in Mexican hard-discount retail, adding non-US, non-healthcare diversification. LifeStance Health at ~3.3% is the behavioral-health services position at a reset valuation. AtriCure at ~3.1% rounds out with electrophysiology and structural-heart exposure.

Asymmetric payoff

If elective-care volumes recover on the historical four-to-six-quarter lag and Invisalign case-starts continue to inflect, the book returns roughly 18-30% annualized over three years as multiples compress back toward fifteen-year medians. If the recovery slips by a year and consumer deferral extends, the book returns -3% to +5% with Cooper, Henry Schein, and Sotera absorbing most of the drawdown through recurring revenue. If the recovery overshoots trend on pent-up demand, the right tail is 32-45%.

At a 55% base, 25% bear, 20% bull weighting, expected value is roughly +13 to +19% annualized against an SPY base rate near +8%. The asymmetry comes from the fact that the cohort still trades as if the bear case is the base case, while the leading indicators are already rolling the other way.

Three things that would change our mind

1. Retail-optical and dental-services same-store growth turning negative again for two consecutive quarters after having inflected positive, which would signal the recovery has stalled rather than accelerated.
2. Align Technology's teen case-start growth falling below five percent year-over-year on a trailing twelve-month basis, indicating the structural adoption curve is breaking rather than the cyclical curve being delayed.
3. Henry Schein or Dentsply Sirona gross margins compressing more than two hundred basis points year-over-year, which would indicate pricing power has eroded structurally and would break the defensible-gross-margin predictor.

What we're explicitly NOT betting on

We are not betting on a single-quarter same-store inflection at any individual holding. We are not betting on a specific Fed cut path. We are not betting on a resumption of COVID-era pent-up demand -- the recovery we underwrite is the normal post-rates-cycle pattern, not a spike. We are not betting on elective cosmetic surgery, aesthetic injectables, or premium-fertility; those are separate categories with different cycle dynamics. The thesis requires only that elective-care volumes recover on the historical reference-class pattern and that gross-margin structure defended through the bear cycle translates into operating-margin expansion on the recovery. Both are testable and partially observable in the most recent two quarters of data.